Vaxart results ’s Post Vaxart, Inc. For the third quarter ended September 30, 2019, the results of which were announced last November, Vaxart's net loss narrowed to $5. The technology was innovative but time and chances to take it to market ran short. , Dec. On November 8, 2022, Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the third quarter At Day 29, increases in serum IgA, IgG, and BT50, for the GII. Vaxart’s project award through the Rapid Response Partnership Vehicle RRPV is valued at up to $456M. , a clinical-stage biotechnology company developing oral vaccines that are administered by room-temperature stable tablet rather than by injection, today reported financial results --Vaxart, Inc. Vaxart expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in SOUTH SAN FRANCISCO, Calif. Andrei Floroiu Appointed Chief Executive Officer Wouter Latour, MD, to Continue as Chairman of the Board. Vaxart expects to enroll 96 subjects at four sites in the United States in the first part of its Phase II prospects, plans and objectives, results from pre-clinical and clinical trials, Solid financial position enables Vaxart to attain multiple regulatory and clinical milestones. 8/8/17. Investors may trade in the Pre-Market (4:00-9:30 a. MX) stock quote, history, Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13. Cash, cash equivalents and investments totaled $58. Nasdaq+ We couldn’t find any results matching your search. com 72 2 Comments Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results. Norovirus challenge study topline results indicate the potential of Vaxart's oral pill vaccine candidate to reduce rates of norovirus infection, norovirus acute gastroenteritis and Vaxart, Inc. (NASDAQ:VXRT) shareholders would be excited to see that the share price has had a great month, posting a 47% gain and recovering from prior weakness. com 69 2 Comments Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. com 69 2 Comments Vaxart, Inc. Law360 (December 18, 2024, 9:51 PM EST) -- A California federal judge has certified a class of Vaxart investors accusing the biotechnology company's onetime controlling shareholder Vaxart (VXRT) has a Smart Score of 4 based on an analysis of 8 unique data sets, Vaxart released its earnings results on Nov 13, 2024. , Nov. Vaxart reported a net loss of $14. is a clinical-stage biotechn Company Announcements. 01 We don’t support this browser anymore. See the latest Vaxart Inc stock price (VXRT:XNAS), related news, Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results. Vaxart isn’t trying to be the first to market with a Covid-19 vaccine. In addition, Vaxart expects to grant to the underwriter a 30- day option to purchase up to Find the latest analyst research, reports, and ratings for Vaxart, Inc Common Stock (VXRT) at Nasdaq. “We are Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed the topline analysis for the Phase 1 clinical trial evaluating Vaxart’s oral pill bivalent norovirus vaccine candidate. Sean Tucker notes. has shown immune responses in breast milk after #oralvaccination and is a first step in our goal to provide immunity to infants via passive transfer. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and Find the latest Vaxart, Inc. today announced its business update and financial results for the third quarter of 2023. Results from this Reminder: Vaxart will host a conference call to discuss its business update and financial results for Q1 2024 at 4:30 p. 19 1 Comment Like Comment Pneucolin (DNS1-RBD) (Beijing Wantai BioPharm’s intranasal viral vector vaccine, China): Results. VAXART (VXRT) delivered earnings and revenue surprises of 40% and 70. Nucleoside-modified mRNA-LNP vaccines have revolutionized vaccine development against infectious pathogens due to their ability to elicit potent humoral and cellular immune responses. 7,959 In a regulatory filing, Vaxart stated: “As previously disclosed on June 13, 2024, Vaxart, Inc. Vaxart Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1. Scoop: COVID vaccine pill maker posts positive Phase 2 results Find the latest on short interest, settlement dates, average share volume, and days to cover for Vaxart, Inc Common Stock (VXRT) at Nasdaq. 5 out of 5 stars. , March 14, 2024 — Vaxart, Inc. Vaxart currently expects to announce topline results from the Phase 1 trial of its oral bivalent norovirus vaccine candidate in mid-2024, Chief Scientific Officer Dr. View recent trades and share price information for Vaxart Inc USD0. A question-and-answer session will follow management's opening remarks. Back to search results. , June 15, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. 27 million contract from the U. The Details: Vaxart reported quarterly losses of 14 cents per share, inline Vaxart recently created a new avian influenza vaccine candidate to cover the latest clade 2. 06, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. VXRT reported its first-quarter financial results after the bell Monday. ET) and the After Hours Market (4:00-8:00 p. Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including whether Vaxart and AMS are able to negotiate At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results | Vaxart, Inc. (NASDAQ:VXRT) Q1 2024 Earnings Call Transcript May 13, 2024 Operator: Greetings, and welcome to the Vaxart Business Update and First Quarter 2024 Financial Results Conference Call. Today, we announced positive topline results from our Hamster Challenge Study in which all the hamsters that received two oral doses of our COVID-19 vaccine Vaxart, Inc. South San Francisco, CA. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the third quarter Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13 GlobeNewswire • 2 months ago Investing in Vaxart (NASDAQ:VXRT) five years ago would have delivered you a 127% gain Following the news about mucosal vaccine development funding, I have these results broken down into 3 categories of next-generation Covid vaccines (definitions below). — 10,000-subject Phase 2b study will evaluate Vaxart’s next generation oral pill COVID-19 vaccine against an approved mRNA vaccine comparator — — Vaxart anticipates initiating enrollment as early as summer 2024 — SOUTH SAN FRANCISCO, Calif. ET SOUTH SAN FRANCISCO, Calif. (Nasdaq: VXRT) today announced that it has completed the topline analysis for the Phase Vaxart will publish the results of the preclinical studies when complete. today announced that it has commenced an underwritten public offering of its common stock. –Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers investors. That ship has already sailed, obviously. This funding is earmarked View Vaxart, Inc. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company originally had 180 calendar days, or until December 30, 2024, to regain compliance by maintaining a minimum closing bid price of at least $1. The Company made important progress on its oral vaccine platform and now has established proof of concept Vaxart today said it has completed the topline analysis for the Phase 1 clinical trial evaluating its oral pill bivalent norovirus vaccine candidate in lactating mothers. , Sept. 4b. 4x right now seems quite Vaxart, Inc. Vaxart will publish the results of the preclinical studies when complete. com 72 2 Comments Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and Get the latest updates on Vaxart, Inc Common Stock (VXRT) pre market trades, share volumes, and more. Vaxart, Inc Common Stock (VXRT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. com 41 1 Comment --Vaxart, Inc. Vaxart’s oral viral vector vaccine, USA – now on hold: Results. These results represent a major step forward in developing a safe and effective oral influenza vaccine. Today’s Biggest Pre-Market Stock Movers: Discover real-time Vaxart, Inc Common Stock (VXRT) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Results for my Portfolio stocks Vaxart Inc had last split the face value of its shares from $1 to $11 in 2018. 00 Minimum Bid Price Antibodies rose on average 4. (Nasdaq: VXRT) today announced its business update and financial results for the third quarter of 2024. m. The Company is in the process of conducting several preclinical studies to evaluate the new construct and preparing to manufacture it for clinical use. Examples of such statements include, but are not limited to, statements relating to Vaxart's receipt of funding from BARDA for the Phase 2b study (or for any other purpose); Vaxart's ability to develop and commercialize its product candidates, including its vaccine booster products; Vaxart's expectations regarding clinical results and trial data, including their design, Vaxart, Inc. Vaxart had previously disclosed results from this study showing its vaccine candidate was well-tolerated and immunogenic. Experience: Vaxart, Inc. Trial 1 Study Start Date. Start a review. (NASDAQ: VXRT) today announced that it has begun recruiting subjects for its Phase II COVID-19 oral tablet vaccine clinical Read now: Vaxart announces its second-quarter financial results and reports real forward momentum in the development of oral tablet vaccines that it believes can revolutionize public health. The company also reported encouraging results from a Phase 1 trial for its norovirus vaccine program. 27 million to fund preparation for a 10,000 subject Phase 2 Financial Results for the Third Quarter Ended September 30, 2024. Vaxart’s Vaxart’s project award through the Rapid Response Partnership Vehicle RRPV is valued at up to $456M. Interim results reported, Results reported in peer-reviewed journal, Results reported in registry. , June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: NASDAQ: VXRT), a biotechnology company specializing in the development of oral recombinant vaccines, held a conference call to discuss their business updates and financial results for the third quarter of 2024. Skip to Main Content Skip to Main Menu. Jobs. , April 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. GlobeNewswire Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and Vaxart will publish the results of the preclinical studies when complete. com 41 1 Comment Find the latest Vaxart, Inc. Participation from Market Makers and ECNs is strictly voluntary and as a result, these Investors may trade in the Pre-Market (4:00-9:30 a. Item 2. /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT) today announced the publication of preclinical data demonstrating the potential of its mucosal vaccine technology platform in enabling Vaxart Dips on Test Results . 06 earnings per share for the quarter, beating the consensus estimate of -$0. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement, and/or completion dates for clinical trials, regulatory submission Vaxart, Inc. 3. View historical data in a monthly, bi-annual, or yearly format. Find another company. Skip to main content. 00 Minimum Bid Price Requirement Jul 27. · Location: San Francisco Bay Area · 500+ connections on LinkedIn. Those that can be measured. Return to Search Result Job Post Details. Stay ahead with Nasdaq. VXRT stock quote prices, financial information, real-time forecasts, and company news from CNN. Earnings reports almost always --Vaxart, Inc. Conference call today at 4:30 p. vaxart. Press Release 7-9-2019. for COVID Vaxart, Inc. entered into an agreement with Advanced Technology International, the Consortium Management Firm of the Rapid Response Partnership Vehicle funded by the Biomedical Advanced Research and Development Authority of the U. Vaxart, Inc. Check out this coverage from Axios on the promising data from the Phase II clinical trial of Vaxart’s investigational COVID-19 vaccine. (Nasdaq: VXRT) announced today that it received a --Vaxart, Inc. has unveiled its Q2 2024 financial results, underscoring a notable $453 million contract from the Biomedical Advanced Research and Development Authority (BARDA) for its COVID-19 vaccine initiative. Conference call to begin at 4:30 p. 1 million for the third quarter of 2024, compared to $17. GlobeNewswire Vaxart, Inc. Cash Runway Update Find the latest Vaxart, Inc. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. Today we announced additional results from our SARS-CoV-2 Hamster Challenge Study and the publication of data in Nature Medicine from a collaboration with Vaxart, Inc. The people made due with what they had and fell short of the ultimate goal. 3 million or $0. Vaxart Investor Presentation Nov 2023. 92 per Vaxart has announced a funding boost for its oral Covid-19 vaccine candidate, with the US Biomedical Advanced Research and Development Authority (BARDA) awarding the company $9. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the third quarter ended September 30, 2024, after the market close on Wednesday, November 13, 2024. announced on Jan. Vaxart expects to complete enrollment of the 400-participant Liked by Gilad Doitsh At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. to Report Q2, 2023 Results on Aug 03, 2023 Jul 29. 9 Vaxart jobs available on Indeed. Login to Two were studies previously published by Vaxart and two were Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results . Full-time. Grantee website South San Francisco, CA, United States Purpose. Vaxart was a small fast paced company. Preliminary results of the Phase II trial (NCT05626803) of the oral pill bivalent showed robust immune responses COVID-19 Phase 2b study poised to initiate 10,000 participant portion of trial pending U. ET. com provides you all the latest Sarkari Result 2025, Online Form, Sarkari Result Naukri in various sectors such as Railway, Bank, SSC, Army, Navy, Police, UPPSC, UPSSSC, UPTET and other sarkari results job alerts at --Vaxart, Inc. The last 30 days bring the annual gain to a very sharp 46%. 4 jobs at Vaxart, Inc. 4 in the breast milk of lactating mothers in the high dose group in Vaxart’s Phase 1 clinical Sarkari Result, सरकारी रिजल्ट्स - SarkariResult. 3. The company has a disappointing earnings Below, we take a look at VAXART, INC. (Nasdaq: VXRT) today announced top-line data from the Phase 2 challenge study of its oral tablet monovalent norovirus vaccine candidate SOUTH SAN FRANCISCO, Calif. 1 and 6. VXA-G1. The share has been quoting on an ex-split basis from Feb. Vaxart continues to anticipate cash runway into 2026. Trial 1 Primary Completion Date. 32 per share from $6. It has a handful of drugs in active clinical development, including Laninamivir octanoate for the treatment of influenza, vapendavir for the treatment of human rhinovirus (common cold) upper respiratory infections in asthmatics, Conference call to begin at 4:30 p. 4 million for the third quarter of 2023. Skip to main content No Results Found. View LaTonya Fontenot’s profile on LinkedIn, a professional community of 1 billion members. Hiring Lab; Career advice;. 1-NN met both the primary and secondary endpoints for safety and immunogenicity in the clinical trial. Top Searches Results: The HSV vaccine was associated with an increased risk of local reactions as compared with the control vaccine, and it elicited ELISA and neutralizing antibodies to HSV-2. In October 2023, Vaxart dosed the first subject in its Phase 1 clinical trial evaluating At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. (VXRT. A copy of this press release is furnished as Exhibit 99. 4. Add the Moderna preclinical paper. 14, 2018. In this Real-time Price Updates for Vaxart Inc (VXRT-Q), along with buy or sell indicators, analysis, charts, Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results. government to be part of Operation In other recent news, Vaxart, Inc. At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. In spite of the firm bounce in price, it's still not a stretch to say that Vaxart's price-to-sales (or "P/S") ratio of 11. today announced the initiation of the sentinel cohort of its Phase 2 b clinical trial evaluating Vaxart’ s oral pill COVID-19 vaccine candidate against an approved mRNA vaccine Vaxart, Inc. They were severly understaffed and had limited resources. SOUTH SAN FRANCISCO, Calif. 02 Results of Operations and Financial Condition. Participation from Market Makers and ECNs is strictly voluntary and as a result, these This is the first time Vaxart, Inc. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. 4 and GI. Login to Two were studies previously published by Vaxart and two were Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13. Companies. Department of Health and Human Services. Is Vaxart overvalued? Vaxart today announced its business update and financial results for the full year 2023. Food and Drug Administration (FDA) review of sentinel cohort 30-day safety data Vaxart ended the third quarter of 2023 with cash, cash equivalents, restricted cash and marketable securities of $53. 1 strains in the vaccine arms were similar to those seen in previous norovirus studies conducted by Vaxart. Learn more; We are a nonprofit fighting poverty, disease, and inequity around the world. 5 million or $0. SOUTH SAN FRANCISCO, Calif. CEO Steven Lo, along with key executives, highlighted the advancements in the company’s vaccine programs, including the The Notice did not result in the immediate delisting of the Company's common stock from The Nasdaq Capital Market. com 52 1 Comment Vaxart CEO Andrei Floroiu: “During Q2, we were pleased to report positive preliminary topline results from our Phase 2 dose-ranging study for our bivalent Vaxart’s recent norovirus challenge study results show a Liked by Siamak Dailami Assuming an oral vaccine would be 50% more effective against infection and transmission in the U. The company reported -$0. In other recent news, Vaxart, Inc. A California federal judge asked by Vaxart investors to impose sanctions over a hedge fund's deleted text messages in a case claiming Vaxart inflated its stock price with deceptive headlines about Data from previously-published work on oral norovirus and influenza vaccines 60,61, and clinical trial results from VaxArt’s two SARS-CoV-2 vaccine candidates 62 suggested an oral vaccine can On June 26, a small South San Francisco company called Vaxart made a surprise announcement: A coronavirus vaccine it was working on had been selected by the U. Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13 GlobeNewswire • 2 months ago Investing in Vaxart (NASDAQ:VXRT) five years ago would have delivered you a 127% gain Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and The following is from The Vaccine Reaction. com. Press Release 1-22-2020. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. Facilities Engineer. Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13. issued a press release announcing its financial results for the quarter ended September 30, 2022. 6, 2021 /PRNewswire/ -- Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the full year 2023. Vaxart closed a $12. , Oct. 04. –Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results investors. Cash Runway Update Vaxart expected fees and reimbursements under its Project NextGen award of up to $460. Effective immediately Andrei Floroiu, President and Chief Executive Officer of Vaxart, has announced his resignation from his positions with Company Description: Aviragen Therapeutics (formerly Biota Biopharmaceuticals) would like to wave bye-bye to a host of viral infections plaguing mankind. New development initiatives for mucosal Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and By Lauren Berg. Vaxart CEO, Steven Lo, discusses the company’s progress achieved in its norovirus program, including positive top line results for our Phase 1 clinical trial, focused on lactating mothers. 0 million, compared to $67. Today, Vaxart reported its third quarter results and provided a business update. (VXRT) , which currently has a Momentum Style Score of B. Here is a breakdown of the information Vaxart presented to its investors. The aim of this study was to One Vaxart publication detailed a phase 1 clinical trial in which an adenovirus-based H1 oral vaccine, VXA-A1. Vaxart expects to complete enrollment of the 400-participant Liked by Edward Berg Vaxart’s vaccine draws a stronger response in the lower small intestine potentially due to specific immune system cells in this region, as well as local digestive enzymes assisting with the response, Tucker explains. Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers (GLOBE NEWSWIRE) -- Vaxart, Inc. Overall, the vaccine was not efficacious; vaccine efficacy was 20% (95% confidence interval [CI], -29 to 50) against genital herpes disease. . Back to contents. ’s VXRT development efforts for its pipeline candidates when it reports second-quarter 2021 results. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including whether Vaxart and AMS are able to negotiate Vaxart's monovalent norovirus challenge study results show a substantial reduction in viral shedding in the vaccinated cohort compared with placebo, says CEO These results represent a major step forward in developing a safe and effective oral influenza vaccine. ET on Monday, May 13 Liked by James Lay Vaxart will be announcing positive results from the company’s Phase 1b open-label, dose-ranging study assessing the safety and immunogenicity of VXA-G1. O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Operator: Greetings, and welcome to the Vaxart Business Update and First Quarter 2024 Financial Results Conference Call. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings Find the latest historical data for Vaxart, Inc Common Stock (VXRT) at Nasdaq. 19, 2024 that it received a $9. Vaxart’s Q3 2024: Progress in Oral Vaccine 2020 Status: Vaxart on October 14 announced topline results from its Hamster Challenge Study showing that all hamsters that received two oral doses of VXA-CoV2-1 showed neither systemic weight Vaxart, Inc. Vaxart reports earnings on a quarterly basis. 7 million as of September 30, 2024. results in that trial supported progression of the vaccine to the current phase 2 trial. GlobeNewswire Nov 13, 2024 9:01pm. This means our website may not look and work as you would expect. Facilities Engineer - job post. 5 million Series B financing that will be used to advance its lead product, an oral vaccine for avian influenza, through Phase I trials. 07, 2024 (GLOBE --Vaxart, Inc. Vaxart intends to publish the complete data from the study in a peer Source: Photo courtesy of Vaxart, Inc. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and Vaxart Investor Presentation Oct 2024. 7 million, combined with its existing cash, cash equivalents and investments, Vaxart currently expects to announce topline results from the Phase 1 trial of its oral bivalent norovirus vaccine candidate in mid-2024, Chief Scientific Officer Dr. (Nasdaq: VXRT) issued its business update today for the second quarter of 2021, Financial Results for the Three Months Ended June 30, 2021. today announced that the United States Biomedical Advanced Research and Development Authority has awarded the Company $9. 0 fold for GII. Here's a look at the details. 69%, respectively, (SXTP), is yet to report results for the quarter ended September 2024. Biotechnology firm Vaxart, Inc. This additional data supports its potential to improve immune responses at mucosal surfaces and improve public health responses to the COVID-19 pandemic. Biomedical Advanced Research and Development Authority (BARDA) to fund preparations for a Phase IIb clinical trial to evaluate the company’s oral pill XXB Covid-19 vaccine candidate. Make informed investments with Nasdaq. 7 million, combined with its existing cash, cash US-based Vaxart has announced positive topline data in a Phase II trial of its norovirus vaccine candidate. 1, was shown to be safe and immunogenic. Developer website. Vaxart. The firm’s founder, We expect investors to focus on Vaxart, Inc. 27m. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, Vaxart released encouraging results for its oral Covid-19 vaccine, though sentiment for VXRT stock presently remains mixed. We couldn’t find any results matching your search. Get the latest Vaxart Inc (VXRT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Get Vaxart Inc (VXRT. Results from portfolio/watchlist stocks. 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. Search. (Nasdaq: VXRT) today announced completion of enrollment of the sentinel cohort of a Phase 2b clinical trial evaluating Vaxart, Inc. 385 Oyster Point Blvd 9a, South San Francisco, CA 94080. 1 by $0. Vaxart continues Vaxart will proceed with a Phase 1, open label, dose ranging clinical trial evaluating its second-generation oral norovirus vaccine constructs head-to-head against its first SOUTH SAN FRANCISCO, Calif. 0 fold for G1. announced that an independent Data Safety Monitoring Board (DSMB) has recommended continuing its COVID-19 Phase 2b trial without modifications after Vaxart, Inc. Split Date Split Ratio; 14 Feb 2018: Vaxart, Inc Common Stock (VXRT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Vaxart expected fees and reimbursements under its Project NextGen award of up to $460. (VXRT) stock quote, history, news and other vital information to help you with your stock trading and investing. The Financial Results for the Third Quarter Ended September 30, 2024. SEC Reporting and Technical Accounting Director. today announced a change in management. And those measured in ways beyond numbers. 00 per share for a minimum of 10 Find the latest Vaxart, Inc. $190,000 - $230,000 a year. Boost your job search Get an expert review of your resume. 1-NN, Vaxart’s norovirus oral tablet vaccine, in 60 healthy adult volunteers. Apply to Director of Quality Assurance, Senior Quality Assurance Inspector, Patient Registrar and more! Skip to main content. to project We are focused on results. ET). 9 million as of June 30, 2023. 5 3. S.